Statistiche di base
| LEI | 529900JXBTG5OB59PM04 |
| CIK | 1051514 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to STRATA Skin Sciences, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| March 26, 2026 |
DESCRIPTION OF OUR COMMON STOCK Exhibit 4.2 DESCRIPTION OF OUR COMMON STOCK General The following description of the material provisions of our capital stock does not purport to be complete and is based on and qualified by our Certificate of Incorporation, as amended and restated (the “Charter”), our Bylaws, and our Warrant Agreement to Purchase Shares of the Common Stock of STRATA Skin Sciences, Inc., dated as of June 30, 2023, |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as speci |
|
| March 26, 2026 |
Exhibit 19.1 STRATA SKIN SCIENCES, INC. Title: INSIDER TRADING POLICY Policy #: COM: 004 Department Ownership: Compliance Approved by and Title: Board of Directors Initial Issue Date: November 4, 2015 Revised Date: October 30, 2024 SCOPE “STRATA” (the “Company”) as used throughout this Policy, refers to the entire Corporate Group and is meant to include all subsidiaries and business offices of the |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-51481 STRATA Skin Sciences, Inc. (Exact name of registrant as specified in i |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-283418 Registration No. 333-273846 Registration No. 333-262150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-283418 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273846 POS |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-283418 Registration No. 333-273846 Registration No. 333-262150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-283418 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273846 POS |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-283418 Registration No. 333-273846 Registration No. 333-262150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-283418 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273846 POS |
|
| February 27, 2026 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2026 As filed with the U.S. Securities and Exchange Commission on February 27, 2026 Registration No. 333-257867 Registration No. 333-226298 Registration No. 333-216712 Registration No. 333-208397 Registration No. 333-189119 Registration No. 333-161286 Registration No. 333-136183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATI |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-51481 STRATA Skin Sciences, Inc. The Nasdaq Stock Market LLC (Exact name of registrant as specified in its charter, and name of Exchange where security is listed and/or registered) |
|
| February 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its Charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 17, 2025 |
Exhibit 99.1 Investor Presentation December 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statemen |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51481 STRATA SKIN SCIENCES, INC. (Exact name of registra |
|
| November 14, 2025 |
AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT Exhibit 10.1 Execution Version AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this day of November, 2025 (“Effective Date”), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this Agreement, the “Borrower”), MIDCAP FINANCIA |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2025 |
STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., November 13, 2025 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results |
|
| October 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| October 20, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its Charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Comm |
|
| October 15, 2025 |
Up to $392,254 of Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283418 AMENDMENT NO. 1 DATED OCTOBER 15, 2025 to Prospectus Supplement dated September 26, 2025 (To Prospectus dated December 18, 2024) Up to $392,254 of Shares Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated September 26, 2025 (the “Prospectus Supplement”). This Amendment sho |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2025 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its Charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commis |
|
| September 26, 2025 |
Strata Skin Sciences, Inc. $1,035,358 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283418 Prospectus Supplement (to Prospectus dated December 18, 2024) Strata Skin Sciences, Inc. $1,035,358 Common Stock We have entered into an Equity Distribution Agreement (Sales Agreement) with Ladenburg Thalmann & Co. Inc. (Ladenburg) relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectu |
|
| September 4, 2025 |
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering Exhibit 99.1 STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering Horsham, Pa., September 4, 2025 - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously an |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 3, 2025 |
Strata Skin Sciences, Inc. 1,097,547 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283418 Prospectus Supplement (to Prospectus dated December 18, 2024) Strata Skin Sciences, Inc. 1,097,547 Shares of Common Stock Strata Skin Sciences, Inc. (the “Company” or “we” or “our” or “us”) is offering (“Offering”) 1,097,547 shares (“Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), pursuant to this pro |
|
| September 3, 2025 |
Exhibit 99.1 STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules HORSHAM, Penn., September 3, 2025 - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic condit |
|
| September 3, 2025 |
Exhibit 1.1 Execution Copy PLACEMENT AGENCY AGREEMENT September 2, 2025 Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34105 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Strata Skin Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to 1,097,547 shares (the “Shares”) of voting co |
|
| September 3, 2025 |
Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 2, 2025, between Strata Skin Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its Charter) Delaware 000-51481 13-3986004 (State or other jurisdiction (Commission (IRS Employe |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its Charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commiss |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 18, 2025 |
Exhibit 99.1 Investor Presentation August 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as |
|
| August 13, 2025 |
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., August 13, 2025 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2025 |
Exhibit 99.1 STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment Strata updates status of non-Excimer laser false advertising litigation Horsham, PA – August 7, 2025 – STRATA Skin Sciences, Inc. (“ST |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 19, 2025 |
Exhibit 99.1 STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care throug |
|
| May 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2025 |
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 14, 2025 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of |
|
| April 25, 2025 |
Exhibit 16.1 April 25, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Strata Skin Sciences, Inc. under Item 4.01 of its Form 8-K dated April 25, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Strata Skin Sciences, Inc. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 April 25, 2025 Date of Report (Date of earliest event reported) STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commissio |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as speci |
|
| March 28, 2025 |
Description of Registrant’s Securities (attached hereto) Exhibit 4.2 DESCRIPTION OF OUR COMMON STOCK General The following description of the material provisions of our capital stock does not purport to be complete and is based on and qualified by our Certificate of Incorporation, as amended and restated (the “Charter”), our Bylaws, and our Warrant Agreement to Purchase Shares of the Common Stock of STRATA Skin Sciences, Inc., dated as of June 30, 2023, |
|
| March 28, 2025 |
Insider Trading Policy (attached hereto) Exhibit 19.1 STRATA SKIN SCIENCES, INC. Title: INSIDER TRADING POLICY Policy #: COM: 004 Department Ownership: Compliance Approved by and Title: Board of Directors Initial Issue Date: November 4, 2015 Revised Date: October 30, 2024 SCOPE “STRATA” (the “Company”) as used throughout this Policy, refers to the entire Corporate Group and is meant to include all subsidiaries and business offices of the |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 27, 2025 |
Exhibit 99.1 STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., March 27, 2025 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its finan |
|
| March 20, 2025 |
Exhibit 99.1 STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light HORSHAM, PA, March 20, 2025 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treat |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 16, 2024 |
STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 December 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attn: Margaret Sawicki Re: Strata Skin Sciences, Inc. (the “Company”) Registration Statement on Form S-3 Filed December 5, 2024 File No. 333-283418 Dear Ms. Sawicki: Pursuant to |
|
| December 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 11, 2024 |
Exhibit 99.1 Investor Presentation December 2024 Driving Value in Dermatology Matching Patients with Clinics for a Win-Win-Win Outcome NASDAQ: SSKN Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements |
|
| December 5, 2024 |
As filed with the Securities and Exchange Commission on December 5, 2024 As filed with the Securities and Exchange Commission on December 5, 2024 Registration No. |
|
| December 2, 2024 |
December 2, 2024 Dolev Rafaeli President and Chief Executive Officer STRATA Skin Sciences, Inc. |
|
| November 22, 2024 |
Exhibit 4.1 STRATA SKIN SCIENCES, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in S |
|
| November 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) STRATA Skin Sciences, Inc. |
|
| November 22, 2024 |
As filed with the Securities and Exchange Commission on November 22, 2024 As filed with the Securities and Exchange Commission on November 22, 2024 Registration No. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registran |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga310680sskn11142024.htm AMENDMENT NO. 3 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 STRATA Skin Sciences, Inc. (Name of Issuer) Common Stock, $0.0 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2024 |
STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., November 13, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results |
|
| November 12, 2024 |
Exhibit 99.1 STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group HORSHAM, Penn., November 11, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic c |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| August 26, 2024 |
EXHIBIT 99.1 STRATA Skin Sciences Files Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group HORSHAM, Penn., August 26, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, has filed a complain |
|
| August 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 14, 2024 |
STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., August 14, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results |
|
| July 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 23, 2024 |
STRATA Skin Sciences Completes $2.1 Million Direct Offering With Participation from Insiders Exhibit 99.1 STRATA Skin Sciences Completes $2.1 Million Direct Offering With Participation from Insiders HORSHAM, Penn., July 23, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously |
|
| July 18, 2024 |
SC 13D/A 1 ea0209650-13da1accelstrata.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* STRATA Skin Sciences, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 86272A 305 (CUSIP Number) Accelmed Partners, L.P. 848 Brickell A |
|
| July 17, 2024 |
Exhibit 99.1 STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear®X photopneumatic device as an effective treatment option, either as monotherapy or in combination with topical or oral treatments, for patients with mild-moderate acne HORSHAM, Pen |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 11, 2024 |
STRATA Skin Sciences Pre-Announces Second Quarter 2024 Financial Results Exhibit 99.1 STRATA Skin Sciences Pre-Announces Second Quarter 2024 Financial Results HORSHAM, Penn., July 11, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 mil |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 25, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2024 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| June 24, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258814 AMENDMENT NO. 1 DATED JUNE 24, 2024 to Prospectus Supplement dated October 15, 2021 (To Prospectus dated October 15, 2021) STRATA Skin Sciences, Inc. Up to $2,718,309 of Shares Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated October 15, 2021 (the “Prospectus Supplemen |
|
| June 4, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STRATA SKIN SCIENCES, INC. Strata Skin Sciences, Inc., a Delaware corporation (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Strata Skin Sciences, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Ne |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as |
|
| May 15, 2024 |
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of |
|
| April 26, 2024 |
STRATA Skin Sciences Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Exhibit 99.1 Strata Skin Sciences Press Release dated April 26, 2024. STRATA Skin Sciences Announces 1-for-10 Reverse Stock Split HORSHAM, Penn., April 26, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, an |
|
| April 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 28, 2024 |
STRATA Skin Sciences, Inc. Clawback Policy (attached hereto) Exhibit 10.39 STRATA SKIN SCIENCES, INC. CLAWBACK POLICY Introduction The Board of Directors of the Company (the “Board”) believes that it is in the best interests of STRATA Skin Sciences, Inc. (the “Company”) and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board ha |
|
| March 28, 2024 |
EXHIBIT 10.26 AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 27th day of March, 2024 (“Effective Date”), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this Agreement, the “Borrower”), MIDCAP FINANCIAL TRUST, as Age |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as speci |
|
| March 28, 2024 |
Description of Registrant’s Securities (attached hereto) Exhibit 4.2 DESCRIPTION OF OUR COMMON STOCK General The following description of the material provisions of our capital stock (which includes a description of securities we may offer pursuant to the registration statement of which this prospectus, as the same may be supplemented, forms a part) does not purport to be complete and is based on and qualified by our Certificate of Incorporation, as ame |
|
| March 27, 2024 |
Exhibit 99.1 STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET HORSHAM, Pa., Mar. 27, 2024 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the trea |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 26, 2024 |
Exhibit 99.1 STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial –Amends certain financial covenants to enhance liquidity and financial flexibility– –Ensures alignment with the Company’s current and future business operations– HORSHAM, Pa., Feb 26, 2024 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical tech |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 21, 2024 |
Exhibit 10.4 Execution Version c/o MidCap Financial Services, LLC, as servicer 7255 Woodmont Avenue, Suite 300 Bethesda, Maryland 20814 www.midcapfinancial.com February 20, 2024 STRATA Skin Sciences, Inc. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 Attn: Christopher Lesovitz, Chief Financial Officer Re: Amendment No. 4 to Credit and Security Agreement with STRATA Skin Sciences, Inc |
|
| February 21, 2024 |
EXHIBIT 10.1 Execution Version LIMITED WAIVER AND AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT This LIMITED WAIVER AND AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 20th day of February, 2024 (“Effective Date”), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this |
|
| February 14, 2024 |
SSKN / STRATA Skin Sciences, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243309d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* STRATA SKIN SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 86272A206 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statemen |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 8, 2024 |
Exhibit 99.1 STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference HORSHAM, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditi |
|
| January 3, 2024 |
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Exhibit 99.1 STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement HORSHAM, Pa., Jan. 3, 2024 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has re |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 29, 2023 |
STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech Exhibit 99.1 STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech Agreement further solidifies the strength and growth of the partnership between STRATA Skin Sciences and Kosmo Meditech HORSHAM, Pa., Dec. 29, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commerci |
|
| December 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| November 15, 2023 |
STRATA Skin Sciences Reports Third Quarter 2023 Revenue Exhibit 99.1 STRATA Skin Sciences Reports Third Quarter 2023 Revenue Company to Host Conference Call and Webcast Today, November 14, 2023, at 4:30 PM ET HORSHAM, Pa., November 14, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, tod |
|
| November 15, 2023 |
Exhibit 99.2 NASDAQ: SSKN 3Q 2023 Earnings Conference Call and Webcast | November 14, 2023 Forward Looking Statements 2 This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “s |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENC |
|
| October 30, 2023 |
Exhibit 10.5 STRATA Skin Sciences, Inc. October 26, 2023 Dear Chris, This Retention Agreement is between Chris Lesovitz (“Employee”) and STRATA Skin Sciences, Inc. (“Strata”). In consideration and acknowledgment of your future contributions to Strata you are hereby entitled to receive a Retention Bonus (as defined below) as an incentive to remain continuously employed through your designated Reten |
|
| October 30, 2023 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement, dated as of October 30, 2023 (this “Agreement”), is made and entered into by and between STRATA Skin Sciences, Inc., a Delaware corporation (“Company”) and Dolev Rafaeli, an adult individual (“Executive”). Terms used herein and not otherwise defined shall have the meanings set forth in Section 11. RECITALS WHEREAS, subject to the terms a |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 26, 2023 Date of Report (Date of earliest event reported) STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-51481 13-3986004 (State or other jurisdiction of incorporation) (Commiss |
|
| October 30, 2023 |
EXHIBIT 10.2 EMPLOYMENT SEPARATION AGREEMENT AND RELEASE THIS EMPLOYMENT SEPARATION AGREEMENT AND RELEASE (“Agreement”) has been entered into, as of October 30, 2023, by and between Robert Moccia, residing at the address on file with the Company (as defined below) (referred to below as “Executive”) and STRATA Skin Sciences, Inc., a Delaware corporation, with its principal place of business at 5 Wa |
|
| October 30, 2023 |
STRATA Skin Science Announces Leadership Change Exhibit 99.1 STRATA Skin Science Announces Leadership Change Bob Moccia Steps Down as CEO and Member of the Board Dr. Dolev Rafaeli, Named New Vice-Chairman, President and CEO HORSHAM, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatolo |
|
| October 30, 2023 |
Exhibit 10.4 STOCK OPTION AGREEMENT (Non-Qualified Stock Option) THIS STOCK OPTION AGREEMENT (this "Agreement"), dated as of October 30, 2023 (the "Grant Date"), is between STRATA SKIN SCIENCES, INC., a Delaware corporation (the "Company"), and Dolev Rafaeli, an adult individual ("Optionee"). NOW, THEREFORE, the parties hereto, in consideration of the mutual covenants contained herein, agree as fo |
|
| September 25, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☒ |
|
| September 12, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) ☐ |
|
| August 18, 2023 |
SC 13G/A 1 sc13ga21068000608182023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 STRATA Skin Sciences, Inc. (Name of Issuer) Common Stock, $0.00 |
|
| August 16, 2023 |
STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 August 16, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Jan Park Re: STRATA Skin Sciences, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-273846 Ladies and Gentlemen: The undersigned hereby r |
|
| August 16, 2023 |
United States securities and exchange commission logo August 16, 2023 Robert Moccia Chief Executive Officer STRATA Skin Sciences, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENCES, I |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 9, 2023 |
STRATA Skin Sciences Reports Second Quarter 2023 Revenue Exhibit 99.1 STRATA Skin Sciences Reports Second Quarter 2023 Revenue Company to Host Conference Call and Webcast Today, August 9, 2023, at 4:30 PM ET HORSHAM, Pa., August 9, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today an |
|
| August 9, 2023 |
Exhibit 10.6 INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT This Intellectual Property Security Agreement Supplement is entered into as of the [] day of July, 2023 by and between MIDCAP FINANCIAL TRUST, a Delaware statutory trust (in such capacity, together with its successors and assigns, “Agent”) and STRATA SKIN SCIENCES, INC., a Delaware corporation (“Strata”, and together with any other P |
|
| August 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) STRATA Skin Sciences, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 11, 2023 |
Exhibit 99.1 STRATA Announces JCAD Publication: Photopneumatic Technology for the Treatment of Mild-to-Moderate Acne Vulgaris HORSHAM, Pa., July 11, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the Journal of Cli |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 6, 2023 |
EXHIBIT 10.5 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of June 30, 2023, between STRATA Skin Sciences, Inc., a Delaware corporation (the “Company”), and MidCap Funding XXVII Trust, a Delaware statutory trust (together with any registered holder from time to time of the Warrant or any hol |
|
| July 6, 2023 |
EXHIBIT 10.3 c/o MidCap Financial Services, LLC, as servicer 7255 Woodmont Avenue, Suite 300 Bethesda, Maryland 20814 www.midcapfinancial.com June 30, 2023 STRATA Skin Sciences, Inc. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 Attn: Christopher Lesovitz, Chief Financial Officer Re: Amendment No. 3 to Credit and Security Agreement with STRATA Skin Sciences, Inc. Ladies and Gentlemen |
|
| July 6, 2023 |
STRATA Skin Sciences Secures additional $12 Million Financing with MidCap Financial EXHIBIT 99.1 STRATA Skin Sciences Secures additional $12 Million Financing with MidCap Financial HORSHAM, Pa., July 6, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has completed the refinancing of its exi |
|
| July 6, 2023 |
EXHIBIT 10.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN |
|
| July 6, 2023 |
EXHIBIT 10.1 AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 30th day of June, 2023 (“Effective Date”), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this Agreement, the “Borrower”), MIDCAP FINANCIAL TRUST, as Agent |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| June 30, 2023 |
STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors EXHIBIT 99.1 STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairma |
|
| May 15, 2023 |
Achieved revenue of $7.6 million for the first quarter 2023 Exhibit 99.1 Press Release dated May 15, 2023 issued by STRATA Skin Sciences, Inc. STRATA Skin Sciences Reports First Quarter 2023 Revenue Achieved revenue of $7.6 million for the first quarter 2023 Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENCES, |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of |
|
| April 12, 2023 |
STRATA Skin Sciences Pre-Announces First Quarter 2023 Results Exhibit 99.1 STRATA Skin Sciences Pre-Announces First Quarter 2023 Results • Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results since first quarter of 2016 • Company exceeds plan with 44 TheraClear®X placements in the first quarter HORSHAM, Pa., Apr. 12, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medica |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as speci |
|
| March 31, 2023 |
Exhibit 10.25 Execution Version AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 6th day of September, 2022 (“Effective Date”), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this Agreement, the “Borrower”), MIDCAP FI |
|
| March 31, 2023 |
STRATA Skin Sciences Reports Record Fourth Quarter 2022 Revenue Exhibit 99.1 STRATA Skin Sciences Reports Record Fourth Quarter 2022 Revenue Achieved record revenue of $36.2 million, representing 21% increase over the year 2021 Company to host conference call and webcast today, March 31, 2023, at 8:30 AM ET HORSHAM, Pa., March 31, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercial |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 13, 2023 |
STRATA Skin Sciences Affirms No Exposure to Silicon Valley Bank Exhibit 99.1 STRATA Skin Sciences Affirms No Exposure to Silicon Valley Bank HORSHAM, Pa., March 13, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it does not have exposure to Silicon Valley Bank. The Company does |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| February 27, 2023 |
STRATA Skin Sciences Announces Regaining Compliance with NASDAQ’S Minimum Price Rule Exhibit 99.1 STRATA Skin Sciences Announces Regaining Compliance with NASDAQ’S Minimum Price Rule HORSHAM, Pa., February 27, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it had been notified by Nasdaq that S |
|
| February 14, 2023 |
SSKN / STRATA Skin Sciences Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236168d29sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* STRATA SKIN SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 86272A206 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 STRATA Skin Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 86272A206 (CUSIP Numbe |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| February 1, 2023 |
STRATA Skin Sciences Expects Record Full Year 2022 Revenue Exhibit 99.1 STRATA Skin Sciences Expects Record Full Year 2022 Revenue ● Unaudited, preliminary revenue within the range of $35-$36 million ● Record revenue represents approximately 17-19% growth over full year 2021 HORSHAM, Pa., February 1, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innova |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) DE 13-3986004 (State or Other Jurisdiction of Inco |
|
| January 9, 2023 |
Investor Presentation dated January 9, 2023, issued by Strata Skin Sciences, Inc. Investor Presentation | January 20232 Main Product Devices XTRAC ® & TheraClear ® X Global Leader Dermatology excimer laser Experienced Management 20+ year history Large Market Opportunity Addressing $38B market Treatment Focus Psoriasis, Vitiligo, Eczema and Acne Company Overview A medical technology company dedicated to developing cutting-edge solutions for the in-office treatment of life-altering skin conditions. |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
|
| January 9, 2023 |
EX-99.1 2 ex99-1.htm STRATA SKIN SCIENCES, INC. PRESS RELEASE DATED JANUARY 9, 2023 Exhibit 99.1 STRATA Skin Sciences Expands into $300 Million Market with Exclusive Distribution Agreement in Mexico HORSHAM, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the |
|
| January 9, 2023 |
Please see attached PDF for document reference. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENC |
|
| November 9, 2022 |
STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results Exhibit 99.1 STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results ? Strong revenue in the third quarter 2022 of $9.4 million, a 22% increase over the third quarter of 2021 ? Strong international sales of $3.3 million, an 82% increase over the third quarter of 2021 ? Announced U.S. commercial launch of TheraClear?X acne therapy system ? Company to host conference call and webcas |
|
| October 28, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| August 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 29, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
|
| August 29, 2022 |
Investor Presentation December 2020 Investor Presentation August 2022 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENCES, I |
|
| August 10, 2022 |
STRATA Skin Sciences Reports Second Quarter 2022 Financial Results EXHIBIT 99.1 STRATA Skin Sciences Reports Second Quarter 2022 Financial Results Horsham, Pa, August 10, 2022 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the second quarter ended June 30, 2022. Recent Highlights ? |
|
| July 25, 2022 |
EXHIBIT 99.1 STRATA Skin Sciences Announces U.S. Commercial Launch of TheraClear?X Acne Therapy System Combination of FDA-Cleared Technology and STRATA?s Partnership Program Delivers Ideal Platform to Enter Estimated $5.5 Billion Acne Care Market Offering Dermatologists New Treatment Option Horsham, Pa, July 25, 2022 ? STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicat |
|
| July 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 22, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of I |
|
| May 19, 2022 |
Investor Presentation December 2020 Investor Presentation May 2022 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| May 18, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2) |
|
| May 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of I |
|
| May 16, 2022 |
STRATA Skin Sciences Names Michael E. Goodman as Head of International Sales EXHIBIT 99.1 STRATA Skin Sciences Names Michael E. Goodman as Head of International Sales Horsham, Pa, May 16, 2022 ? STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that Michael E. Goodman has been named STRATA?s Head of International Sal |
|
| May 11, 2022 |
Exhibit 10.3 PERFORMANCE STOCK OPTION AGREEMENT (Non-Qualified Stock Option) THIS PERFORMANCE STOCK OPTION AGREEMENT (this "Agreement"), dated as of March 30, 2022 (the "Grant Date"), is between STRATA SKIN SCIENCES, INC., a Delaware corporation (the "Company"), and Robert J. Moccia, an adult individual ("Optionee"). R E C I T A L S A. The Company has adopted the Amended and Restated STRATA Skin S |
|
| May 11, 2022 |
STRATA Skin Sciences Reports First Quarter 2022 Financial Results EXHIBIT 99.1 STRATA Skin Sciences Reports First Quarter 2022 Financial Results Horsham, Pa, May 11, 2022 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights ? Rev |
|
| May 11, 2022 |
Exhibit 10.2 DEVELOPMENT AGREEMENT by and between THERAVANT CORPORATION with offices at 455 North Canyons Parkway, Suite B Livermore, CA 94551 (hereinafter referred to "Party A") and STRATA SKIN SCIENCES, INC. with offices at 5 Walnut Grove, Suite 140 Horsham, Pennsylvania 19044 (hereinafter referred to "Party B") For Development Efforts of: Healthcare products and methods for the medical aestheti |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of I |
|
| May 11, 2022 |
Exhibit 10.4 VWAP PERFORMANCE STOCK OPTION AGREEMENT (Non-Qualified Stock Option) THIS VWAP PERFORMANCE STOCK OPTION AGREEMENT (this "Agreement"), dated as of March 30, 2022 (the "Grant Date"), is between STRATA SKIN SCIENCES, INC., a Delaware corporation (the "Company"), and Robert Moccia, an adult individual ("Optionee"). R E C I T A L S A. The Company has adopted the Amended and Restated STRATA |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENCES, |
|
| April 1, 2022 |
EXHIBIT 99.1 Investor Presentation December 2020 Investor Presentation April 2022 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company?s plans, objectives, expectations and inten |
|
| April 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| March 21, 2022 |
STRATA Skin Sciences Reports Record Fourth Quarter 2021 Revenue EXHIBIT 99.1 STRATA Skin Sciences Reports Record Fourth Quarter 2021 Revenue Horsham, Pa, March 21, 2022 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021. Recen |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 21, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| March 21, 2022 |
Exhibit 4.16 DESCRIPTION OF OUR COMMON STOCK General The following description of the material provisions of our capital stock (which includes a description of securities we may offer pursuant to the registration statement of which this prospectus, as the same may be supplemented, forms a part) does not purport to be complete and is based on and qualified by our Certificate of Incorporation, as am |
|
| March 21, 2022 |
Exhibit 10.79 August 2, 2021 [Executive Name] [Home Address] [Home Address] Re: Severance Agreement Dear : STRATA Skin Sciences, Inc., a Delaware corporation (the ?Company?) considers it essential and in the best interests of its stockholders to foster the continuous employment of key management personnel. In this regard, the Board of Directors of the Company (the ?Board?) recognizes that the poss |
|
| March 21, 2022 |
Exhibit 10.84 LIMITED CONSENT AND AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT This LIMITED CONSENT AND AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is made as of this 10th day of January, 2022 (?Effective Date?), by and among STRATA SKIN SCIENCES, INC., a Delaware corporation (together with each of its subsidiaries that hereafter becomes a party to this Agreement, the ? |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as speci |
|
| March 14, 2022 |
Investor Presentation December 2020 Investor Presentation March 2022 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| March 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction of |
|
| February 14, 2022 |
STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors EXHIBIT 99.1 STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors Horsham, Pa, February 14, 2022 ? STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been ap |
|
| February 14, 2022 |
SSKN / STRATA Skin Sciences Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* STRATA SKIN SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 86272A206 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| February 9, 2022 |
EXHIBIT 99.1 STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum? 1.0 and First Installation in the U.S. Horsham, Pa, February 9, 2022 ? STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced its commercial launch, with the first i |
|
| February 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| January 19, 2022 |
STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 January 19, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Lauren S. Hamill, Esq. Re: STRATA Skin Sciences, Inc. (the ?Company?) Registration Statement on Form S-3 File No. 333-262150 Ladies and Gentlemen: The under |
|
| January 19, 2022 |
United States securities and exchange commission logo January 19, 2022 Robert Moccia Chief Executive Officer STRATA Skin Sciences, Inc. |
|
| January 18, 2022 |
EXHIBIT 99.1 STRATA Skin Sciences Expands into Israel with Leading Medical Device Distributor Enables STRATA to Commercialize and Market its XTRAC Excimer Lasers to an Estimated 300,000 Psoriasis and 160,000 Vitiligo Patients in Israel Horsham, Pa, January 18, 2022 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innova |
|
| January 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| January 14, 2022 |
SSKN / STRATA Skin Sciences Inc / 22NW Fund, LP - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 STRATA Skin Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 86272A206 (CUSIP Number |
|
| January 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the common stock, $0.001 par value per share, of STRATA Skin Sciences, Inc., a Delaware corporation. Th |
|
| January 13, 2022 |
As filed with the Securities and Exchange Commission on January 13, 2022 As filed with the Securities and Exchange Commission on January 13, 2022 Registration No. |
|
| January 10, 2022 |
STRATA Skin Sciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results EXHIBIT 99.1 STRATA Skin Sciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results Horsham, Pa, January 10, 2022 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today reported preliminary, unaudited fourth quarter 2021 financial |
|
| January 10, 2022 |
Investor Presentation December 2020 Investor Presentation January 2022 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| January 10, 2022 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT between and among THERAVANT CORPORATION, as Seller and STRATA SKIN SCIENCES, INC., as Buyer and ASHISH BHATIA, FRANCESCO LUCARELLI AND ROBERT ANDERSON, solely for purposes of Section 5(h) and [ASHISH BHATIA], in his capacity as the Seller?s Representative * * * * Dated as of January 10, 2022 i ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agree |
|
| January 10, 2022 |
EXHIBIT 99.1 STRATA Skin Sciences Announces Acquisition of Acne Treatment Device Assets from Theravant Corporation ? Substantially broadens STRATA?s opportunity with expansion potential into the estimated $5.5 billion U.S. acne care market ? Leverages STRATA?s innovative marketing platform, commercial team and worldwide distributor network to drive additional revenue growth ? Creates a robust pipe |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| December 9, 2021 |
STRATA Skin Sciences Announces Board of Directors Transition Exhibit 99.1 STRATA Skin Sciences Announces Board of Directors Transition Horsham, Pa, December 9, 2021 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021. Mr. |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2021 STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-51481 13-3986004 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 23, 2021 |
STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 CORRESP 1 filename1.htm STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 November 23, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Ada D. Sarmento Re: STRATA Skin Sciences, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-261090 Ladies and Ge |
|
| November 22, 2021 |
As filed with the Securities and Exchange Commission on November 22, 2021 As filed with the Securities and Exchange Commission on November 22, 2021 Registration No. |
|
| November 19, 2021 |
United States securities and exchange commission logo November 19, 2021 Robert J. Moccia Chief Executive Officer STRATA Skin Sciences, Inc. 5 Walnut Grove Drive, Suite 140 Horsham, PA 19044 Re: STRATA Skin Sciences, Inc. Registration Statement on Form S-3 Filed November 16, 2021 File No. 333-261090 Dear Mr. Moccia: This is to advise you that we have not reviewed and will not review your registrati |
|
| November 16, 2021 |
As filed with the Securities and Exchange Commission on November 16, 2021 Registration No. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-51481 STRATA SKIN SCIENC |
|
| November 12, 2021 |
Form of Management Change in Control Agreement EXHIBIT 10.6 Date EMPLOYEE NAME ADDRESS Re: Severance Agreement Dear FIRST NAME: STRATA Skin Sciences, Inc., a Delaware corporation (the ?Company?) considers it essential and in the best interests of its stockholders to foster the continuous employment of key management personnel. In this regard, the Board of Directors of the Company (the ?Board?) recognizes that the possibility of a termination o |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| November 10, 2021 |
STRATA Skin Sciences Reports Third Quarter 2021 Financial Results EXHIBIT 99.1 STRATA Skin Sciences Reports Third Quarter 2021 Financial Results Horsham, Pa, November 10, 2021 ?STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended September 30, 2021. Third Quarter 2021 H |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| October 18, 2021 |
Exhibit 10.1 STRATA SKIN SCIENCES, INC. $11,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT October 15, 2021 Ladenburg Thalmann & Co. Inc. 640 5th Avenue, 4th Floor New York, New York 10019 Ladies and Gentlemen: STRATA Skin Sciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc., as follows: 1. Issuance and Sale of Sha |
|
| October 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction |
|
| October 15, 2021 |
STRATA Skin Sciences, Inc. $11,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333?258814 PROSPECTUS SUPPLEMENT (To Prospectus filed with Form S?3 on August 13, 2021) STRATA Skin Sciences, Inc. $11,000,000 Common Stock We have entered into an Equity Distribution Agreement (Sales Agreement) with Ladenburg Thalmann & Co. Inc. (Ladenburg) relating to shares of our common stock offered by this prospectus supplement and the accomp |
|
| October 13, 2021 |
STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 CORRESP 1 filename1.htm STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 October 13, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Laura Crotty Re: STRATA Skin Sciences, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-258814 Ladies and Gentle |
|
| October 12, 2021 |
As filed with the Securities and Exchange Commission on October 12, 2021 As filed with the Securities and Exchange Commission on October 12, 2021 Registration No. |
|
| October 4, 2021 |
EX-10.3 4 ex10-3.htm WARRANT AGREEMENT EXHIBIT 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINIO |
|
| October 4, 2021 |
EX-10.5 6 ex10-5.htm LESOVITZ EMPLOYMENT AGREEMENT DATED 10-04-21 EXHIBIT 10.5 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT, dated as of October 4, 2021 (this "Agreement"), by and between Strata Skin Sciences, Inc. (the "Company"), a Delaware corporation, and Christopher Lesovitz("Employee"), an individual. W I T N E S E T H: WHEREAS, Employee is currently the Controller of the Company and the Compan |
|
| October 4, 2021 |
EX-10.2 3 ex10-2.htm INTELLECTUAL PROPERTY SECURITY AGREEMENT EXHIBIT 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement is entered into as of the 30th day of September, 2021 by and between MIDCAP FINANCIAL TRUST, a Delaware statutory trust (in such capacity, together with its successors and permitted assigns, “Agent”) and STRATA SKIN SCIENCES, INC., a Dela |
|
| October 4, 2021 |
EX-10.4 5 ex10-4.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 30, 2021, between STRATA Skin Sciences, Inc., a Delaware corporation (the “Company”), and MidCap Funding XXVII Trust, a Delaware statutory trust (together with any registered holder from time to time of the Warr |
|
| October 4, 2021 |
STRATA Skin Sciences Announces CFO Transition EX-99.1 7 ex99-1.htm STRATA PRESS RELEASE, DATED 10-4-21 EXHIBIT 99.1 STRATA Skin Sciences Announces CFO Transition Horsham, PA, October 4, 2021- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Mr. Christopher Lesovitz, STRATA's curr |
|
| October 4, 2021 |
EX-10.1 2 ex10-1.htm CREDIT & SECURITY AGREEMENT EXHIBIT 10.1 CREDIT AND SECURITY AGREEMENT This CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated as of September 30, 2021 (the “Closing Date”) by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“MidCap”), as administrative agent, the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from t |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdictio |
|
| August 25, 2021 |
EXHIBIT 99.1 Investor Presentation December 2020 Investor Presentation August 2021 Driving Value to Dermatology Partners Matching Patients with Clinics Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company?s plans, objectives, expectations and inte |
|
| August 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 25, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
|
| August 19, 2021 |
United States securities and exchange commission logo August 19, 2021 Robert Moccia Chief Executive Officer STRATA Skin Sciences, Inc. |
|
| August 17, 2021 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN STRATA SKIN SCIENCES, INC. AND RA MEDICAL SYSTEMS, INC. DATED AS OF AUGUST 16, 2021 TABLE OF CONTENTS SECTION 1. PURCHASE AND SALE 1 1.1 Assets to be Purchased and Sold 1 1.2 Excluded Assets 1 1.3 Assumed Liabilities 1 1.4 Excluded Liabilities 2 1.5 Purchase Price 3 1.6 Allocation of Purchase Price 4 1.7 Absence of Consents 4 1.8 Closing; Closin |
|
| August 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2021 STRATA Skin Sciences, Inc. (Exact Name of Registrant as Specified in Its Charter) 000-51481 (Commission File Number) Delaware 13-3986004 (State or Other Jurisdiction o |
